Join Growin Stock Community!

Century therapeutics, inc.IPSC.US Overview

US StockHealthcare
(No presentation for IPSC)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

IPSC AI Insights

IPSC Overall Performance

IPSC AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

IPSC Recent Performance

0.65%

Century therapeutics, inc.

0.05%

Avg of Sector

-0.31%

S&P500

IPSC PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

IPSC Key Information

IPSC Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

IPSC Profile

Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.

Price of IPSC

IPSC FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

IPSC Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.30
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1.79
PB Ratio
1.11
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-23.36%
Revenue Growth (YoY)
4121.12%
Profit Growth (YoY)
4121.12%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.30
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1.79
PB Ratio
1.11
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-23.36%
Revenue Growth (YoY)
4121.12%
Profit Growth (YoY)
4121.12%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is IPSC's latest earnings report released?

    The most recent financial report for Century therapeutics, inc. (IPSC) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating IPSC's short-term business performance and financial health. For the latest updates on IPSC's earnings releases, visit this page regularly.

  • How is IPSC's revenue growth?

    In the latest financial report, Century therapeutics, inc. (IPSC) announced revenue of 0, with a Year-Over-Year growth rate of -100%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does IPSC have?

    At the end of the period, Century therapeutics, inc. (IPSC) held Total Cash and Cash Equivalents of 57.83M, accounting for 0.24 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is IPSC's EPS continuing to grow?

    According to the past four quarterly reports, Century therapeutics, inc. (IPSC)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.4. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of IPSC?

    Century therapeutics, inc. (IPSC)'s Free Cash Flow (FCF) for the period is -25.78M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 6.28% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.